Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
India
· Delayed Price · Currency is INR 3,135.50
+7.70 (0.25%)
Jun 3, 2025, 11:30 AM IST
Torrent Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Operating Revenue | 113,170 | 107,278 | 96,202 | 85,080 | 80,046 | Upgrade
|
| Other Revenue | 1,990 | - | - | - | - | Upgrade
|
| Revenue | 115,160 | 107,278 | 96,202 | 85,080 | 80,046 | Upgrade
|
| Revenue Growth (YoY) | 7.35% | 11.51% | 13.07% | 6.29% | 0.82% | Upgrade
|
| Cost of Revenue | 27,760 | 26,862 | 27,352 | 24,420 | 21,464 | Upgrade
|
| Gross Profit | 87,400 | 80,416 | 68,850 | 60,660 | 58,582 | Upgrade
|
| Selling, General & Admin | 22,030 | 20,166 | 17,052 | 15,483 | 14,597 | Upgrade
|
| Other Operating Expenses | 28,160 | 26,573 | 23,377 | 20,865 | 19,184 | Upgrade
|
| Operating Expenses | 58,140 | 54,693 | 47,449 | 42,967 | 40,354 | Upgrade
|
| Operating Income | 29,260 | 25,724 | 21,400 | 17,693 | 18,228 | Upgrade
|
| Interest Expense | -2,520 | -3,526 | -3,322 | -2,529 | -3,508 | Upgrade
|
| Interest & Investment Income | - | 114.8 | 147.8 | 71.5 | 50.7 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -39.1 | -180.8 | 1,695 | 319.7 | Upgrade
|
| Other Non Operating Income (Expenses) | 50 | 314.4 | 61.1 | 76 | 21.7 | Upgrade
|
| EBT Excluding Unusual Items | 26,790 | 22,587 | 18,106 | 17,007 | 15,112 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -4,847 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 170 | 179.9 | 195.1 | 101.4 | 155.8 | Upgrade
|
| Gain (Loss) on Sale of Assets | 10 | -0.2 | 216.2 | - | - | Upgrade
|
| Asset Writedown | - | -129.7 | -45.6 | -2.3 | -4.8 | Upgrade
|
| Other Unusual Items | -240 | 883.8 | - | - | - | Upgrade
|
| Pretax Income | 26,730 | 23,521 | 18,472 | 12,259 | 15,263 | Upgrade
|
| Income Tax Expense | 7,620 | 6,957 | 6,019 | 4,487 | 2,744 | Upgrade
|
| Earnings From Continuing Operations | 19,110 | 16,564 | 12,452 | 7,772 | 12,519 | Upgrade
|
| Net Income | 19,110 | 16,564 | 12,452 | 7,772 | 12,519 | Upgrade
|
| Net Income to Common | 19,110 | 16,564 | 12,452 | 7,772 | 12,519 | Upgrade
|
| Net Income Growth | 15.37% | 33.02% | 60.22% | -37.92% | 22.17% | Upgrade
|
| Shares Outstanding (Basic) | 338 | 338 | 338 | 338 | 338 | Upgrade
|
| Shares Outstanding (Diluted) | 338 | 338 | 338 | 338 | 338 | Upgrade
|
| Shares Change (YoY) | -0.01% | - | - | - | - | Upgrade
|
| EPS (Basic) | 56.47 | 48.94 | 36.79 | 22.96 | 36.99 | Upgrade
|
| EPS (Diluted) | 56.47 | 48.94 | 36.79 | 22.96 | 36.99 | Upgrade
|
| EPS Growth | 15.38% | 33.02% | 60.22% | -37.92% | 22.17% | Upgrade
|
| Free Cash Flow | 19,740 | 28,333 | 17,942 | 16,004 | 16,702 | Upgrade
|
| Free Cash Flow Per Share | 58.33 | 83.72 | 53.01 | 47.29 | 49.35 | Upgrade
|
| Dividend Per Share | 32.000 | 28.000 | 22.000 | 16.500 | 17.500 | Upgrade
|
| Dividend Growth | 14.29% | 27.27% | 33.33% | -5.71% | 105.88% | Upgrade
|
| Gross Margin | 75.89% | 74.96% | 71.57% | 71.30% | 73.19% | Upgrade
|
| Operating Margin | 25.41% | 23.98% | 22.25% | 20.80% | 22.77% | Upgrade
|
| Profit Margin | 16.59% | 15.44% | 12.94% | 9.13% | 15.64% | Upgrade
|
| Free Cash Flow Margin | 17.14% | 26.41% | 18.65% | 18.81% | 20.87% | Upgrade
|
| EBITDA | 37,210 | 33,249 | 28,026 | 23,823 | 24,291 | Upgrade
|
| EBITDA Margin | 32.31% | 30.99% | 29.13% | 28.00% | 30.35% | Upgrade
|
| D&A For EBITDA | 7,950 | 7,526 | 6,626 | 6,130 | 6,063 | Upgrade
|
| EBIT | 29,260 | 25,724 | 21,400 | 17,693 | 18,228 | Upgrade
|
| EBIT Margin | 25.41% | 23.98% | 22.25% | 20.80% | 22.77% | Upgrade
|
| Effective Tax Rate | 28.51% | 29.58% | 32.59% | 36.60% | 17.98% | Upgrade
|
| Revenue as Reported | 115,390 | 107,858 | 96,653 | 87,046 | 80,615 | Upgrade
|
Updated Jan 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.